Ainos (AIMD) Competitors $0.55 +0.01 (+2.81%) As of 05/1/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. PLUR, ALGS, SCLX, KZR, INKT, ATHE, MRNS, ALLK, BCAB, and GBIOShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Pluri (PLUR), Aligos Therapeutics (ALGS), Scilex (SCLX), Kezar Life Sciences (KZR), MiNK Therapeutics (INKT), Alterity Therapeutics (ATHE), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), BioAtla (BCAB), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Pluri Aligos Therapeutics Scilex Kezar Life Sciences MiNK Therapeutics Alterity Therapeutics Marinus Pharmaceuticals Allakos BioAtla Generation Bio Ainos (NASDAQ:AIMD) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Which has stronger earnings & valuation, AIMD or PLUR? Ainos has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$20.73K405.76-$13.77M-$1.65-0.33Pluri$678K50.47-$20.89M-$5.60-0.87 Does the MarketBeat Community prefer AIMD or PLUR? Ainos and Pluri both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformAinosN/AN/APluriN/AN/A Which has more risk and volatility, AIMD or PLUR? Ainos has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Is AIMD or PLUR more profitable? Ainos has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Ainos' return on equity of -75.16% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets AinosN/A -75.16% -50.22% Pluri -3,551.49%-2,778.13%-83.61% Does the media refer more to AIMD or PLUR? In the previous week, Pluri had 3 more articles in the media than Ainos. MarketBeat recorded 4 mentions for Pluri and 1 mentions for Ainos. Ainos' average media sentiment score of 0.93 beat Pluri's score of 0.57 indicating that Ainos is being referred to more favorably in the media. Company Overall Sentiment Ainos Positive Pluri Positive Do institutionals and insiders believe in AIMD or PLUR? 16.6% of Pluri shares are held by institutional investors. 10.4% of Ainos shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAinos beats Pluri on 9 of the 13 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.41M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.337.3222.5118.54Price / Sales405.76241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.106.486.734.25Net Income-$13.77M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.58%1.38%1.03%1 Month Performance1.87%5.00%2.79%2.70%1 Year Performance-47.60%-3.72%15.41%4.05% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos0.5692 of 5 stars$0.55+2.8%N/A-48.1%$8.41M$20,729.00-0.3340PLURPluri0.5947 of 5 stars$4.62-3.8%N/A-8.9%$32.32M$678,000.00-0.82150Upcoming EarningsALGSAligos Therapeutics3.8907 of 5 stars$5.25-0.9%$70.00+1,233.3%-68.7%$32.10M$3.95M-0.3990Upcoming EarningsGap UpSCLXScilex3.1216 of 5 stars$4.61-6.9%$455.00+9,769.8%-83.0%$32.08M$56.59M-5.5580High Trading VolumeKZRKezar Life Sciences3.9365 of 5 stars$4.39+1.4%$39.50+799.8%-47.5%$32.07M$7M-0.3360Upcoming EarningsNews CoverageGap UpINKTMiNK Therapeutics2.7619 of 5 stars$7.86+4.8%$37.50+377.1%-19.0%$31.17MN/A-2.0230Positive NewsATHEAlterity Therapeutics1.807 of 5 stars$3.47-0.3%$12.00+245.8%+55.0%$30.77MN/A0.0010Short Interest ↑Positive NewsMRNSMarinus Pharmaceuticals1.9429 of 5 stars$0.55-0.2%$4.79+771.6%-62.6%$30.32M$30.99M-0.22110Upcoming EarningsALLKAllakos4.6045 of 5 stars$0.330.0%$2.00+513.5%-71.1%$29.46MN/A-0.16190Upcoming EarningsShort Interest ↓Positive NewsBCABBioAtla2.8785 of 5 stars$0.50+11.4%$6.00+1,111.1%-85.2%$28.93M$11M-0.2960Upcoming EarningsNews CoverageGBIOGeneration Bio3.5874 of 5 stars$0.42-2.1%$7.33+1,636.1%-84.9%$28.31M$19.89M-0.19150Positive News Related Companies and Tools Related Companies PLUR Competitors ALGS Competitors SCLX Competitors KZR Competitors INKT Competitors ATHE Competitors MRNS Competitors ALLK Competitors BCAB Competitors GBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AIMD Stock Free AIMD Stock Alerts